See more : Texas Pacific Land Corporation (TPL) Income Statement Analysis – Financial Results
Complete financial analysis of Eusol Biotech Co.,Ltd. (6652.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eusol Biotech Co.,Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Super Bakers (India) Limited (SUPERBAK.BO) Income Statement Analysis – Financial Results
- Gryphon Digital Mining, Inc. (GRYP) Income Statement Analysis – Financial Results
- Iridium Communications Inc. (0JDO.L) Income Statement Analysis – Financial Results
- US Financial 15 Split Corp (FTU.TO) Income Statement Analysis – Financial Results
- Apollo Hospitals Enterprise Limited (APOLLOHOSP.BO) Income Statement Analysis – Financial Results
Eusol Biotech Co.,Ltd. (6652.TWO)
About Eusol Biotech Co.,Ltd.
Eusol Biotech Co.,Ltd. focuses on research and development of new biotech drugs for sleep disorders. Its pipeline includes ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for repairing neuron function; and SM-1, a 3-in-1 capsule containing 3 commercial drugs with sedative effect. The company was founded in 1994 and is headquartered in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.03M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -4.03M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 24.76M | 52.38M | 97.88M | 92.59M | 89.41M |
| General & Administrative | 16.72M | 24.38M | 24.89M | 21.66M | 24.58M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.72M | 24.38M | 24.89M | 21.66M | 24.58M |
| Other Expenses | 0.00 | 62.68M | -1.32M | 343.00K | 0.00 |
| Operating Expenses | 41.48M | 76.76M | 122.77M | 114.24M | 108.75M |
| Cost & Expenses | 41.48M | 76.76M | 122.77M | 114.24M | 108.75M |
| Interest Income | 4.63M | 2.01M | 723.00K | 540.00K | 0.00 |
| Interest Expense | 142.00K | 218.00K | 217.00K | 138.00K | 0.00 |
| Depreciation & Amortization | 4.03M | 23.19M | 28.21M | 29.41M | 24.05M |
| EBITDA | -44.95M | 11.12M | -95.15M | -83.95M | -89.94M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -41.48M | -12.07M | -123.36M | -113.36M | -113.99M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -7.64M | 64.47M | -810.00K | 745.00K | 6.73M |
| Income Before Tax | -49.12M | -12.29M | -123.58M | -113.50M | -107.26M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.49M | 6.02M | -271.00K | 271.00K | 0.00 |
| Net Income | -51.61M | -18.31M | -123.31M | -113.77M | -107.26M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.38 | -0.13 | -0.92 | -0.91 | -0.86 |
| EPS Diluted | -0.38 | -0.13 | -0.92 | -0.91 | -0.86 |
| Weighted Avg Shares Out | 137.00M | 137.00M | 134.04M | 125.00M | 125.00M |
| Weighted Avg Shares Out (Dil) | 135.82M | 137.00M | 134.04M | 125.00M | 125.00M |
Source: https://incomestatements.info
Category: Stock Reports